We propose that a combination of reported biomarkers, for example GM-CSF and the inflammatory protein MRP8/14 or certain micro-RNAs, could predict responsiveness to anti-TNFα in most RA patient cohorts more reproducibly [22, 26]. This evidence concerns the gene TNF and rheumatoid arthritis.